A service of StreetInsider.com
Welcome

Most Popular

AAPL 196.19
C 3.18
GOOG 536.44
BAC 14.47
RIMM 66.15

Recently Added

TNGN 0.00
SWS 12.17
ATHX 2.88
MED 17.54
DANA 0.20

Gaining Speed

MKSI 18.55
CTGI 0.14
HLXW 1.03
BTI 65.46
SOA 13.38
1.66 +0.09 (5.66%) LGND

Click Here to Receive Instant E-mail and RSS Alerts

Stock Details

Last Trade:1.66 Change:+0.09 (5.66%) Prev Close:1.57 Open: 1.59 Days Range:1.59 – 1.69 52 Week Range: 1.55 - 3.21 Volume:640969 P/E: N/A
EPS:-0.87

Member Comments

No member comments available for LGND


Not logged in - Log in or Sign up to leave comments

View AllRecent Alerts 02/09/10

Recent Alert on 02/09/10 at 8:14am
Ligand Pharmaceuticals (LGND) Tops Q4 EPS by 3c on Strong Revenues; Guides for 2010

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reports Q4 EPS of $0.01, 3 cents better than estimates. Revenues were $13.98 million vs. $7.97 million consensus. For 2010, Ligand currently estimates total revenues of approximately $30... Read More

Recent Alert on 02/09/10 at 8:14am
Ligand Pharmaceuticals (LGND) Tops Q4 EPS by 3c on Strong Revenues; Guides for 2010
Recent Alert on 01/07/10 at 3:10pm
Ligand Pharmaceuticals (LGND) Receives $1 Million Milestone Payment From Merck (MRK) Subsidiary
Recent Alert on 12/18/09 at 9:10am
Ligand Pharma (LGND) Partner Glaxo (GSK) Receives Positive Opinion for Revolade from CHMP
Recent Alert on 12/18/09 at 9:10am
Ligand Pharma (LGND) Partner Glaxo (GSK) Receives Positive Opinion for Revolade from CHMP

View AllRecent Press Releases

Press Release on 02/09/10 at 8:00am
Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results

View AllRecent SEC Filings

SEC Filing on 02/09/10 at 8:02am
Form 8-K LIGAND PHARMACEUTICALS For: Feb 09
SEC Filing on 02/08/10 at 4:43pm
Form 8-K LIGAND PHARMACEUTICALS For: Feb 02

View AllRecent Blog Posts

Blog Posts on 02/09/10 at 1:20pm
Ligand Pharmaceuticals Incorporated Q4 2009 Earnings Call Transcript
Blog Posts on 11/09/09 at 3:21pm
Three Core Biotech Holdings: Isis, Ligand and Vical
Blog Posts on 11/01/09 at 3:26am
This Week in Biotech: More Treats than Tricks
Blog Posts on 09/20/09 at 4:50pm
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Blog Posts on 09/11/09 at 5:49am
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up